Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab (AMG 145) in Japan

NCT02808403 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02808403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02808403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab (AMG 145) in Japan
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
June 24, 2016
Completion date
March 30, 2023
Enrollment
6,000 (actual)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

familial hypercholesterolemia, hypercholesterolemia